Key result
Cardiogenic shock carries ~26% 30-day mortality, driven predominantly by non-ischemic etiologies.
Why the study?
Published data on cardiogenic shock are scarce and largely limited to small registries of selected populations.
Observational (n=772)
Yes
In a contemporary, unselected cohort of cardiogenic shock patients, non-ischaemic causes accounted for over 60% of cases, and 30-day mortality was 26.0%, driven by age, low LVEF, and the need for organ support.
30-day mortality remains high in unselected cardiogenic shock with non-ischaemic predominance; extends scarce prior registries but is hypothesis-generating.
AIMS: Published data on cardiogenic shock (CS) are scarce and are mostly focused on small registries of selected populations. The aim of this study was to examine the current CS picture and define the independent correlates of 30 day mortality in a large non-selected cohort. METHODS AND RESULTS: FRENSHOCK is a prospective multicentre observational survey conducted in metropolitan French intensive care units and intensive cardiac care units between April and October 2016. There were 772 patients enrolled (mean age 65.7 ± 14.9 years; 71.5% male). Of these patients, 280 (36.3%) had ischaemic CS. Organ replacement therapies (respiratory support, circulatory support or renal replacement therapy) were used in 58.3% of patients. Mortality at 30 days was 26.0% in the overall population (16.7% to 48.0% depending on the main cause and first place of admission). Multivariate analysis showed that six independent factors were associated with a higher 30 day mortality: age [per year, odds ratio (OR) 1.06, 95% confidence interval (CI): 1.04-1.08], diuretics (OR 1.74, 95% CI: 1.05-2.88), circulatory support (OR 1.92, 95% CI: 1.12-3.29), left ventricular ejection fraction <30% (OR 2.15, 95% CI: 1.40-3.29), norepinephrine (OR 2.55, 95% CI: 1.69-3.84), and renal replacement therapy (OR 2.72, 95% CI: 1.65-4-49). CONCLUSIONS: Non-ischaemic CS accounted for more than 60% of all cases of CS. CS is still associated with significant but variable short-term mortality according to the cause and first place of admission, despite frequent use of haemodynamic support, and organ replacement therapies.
No takes yet. Share an insight, caveat, or question.
Delmas et al. (2021) conducted an observational in Cardiogenic shock (n=772). Cardiogenic shock was evaluated on 30-day mortality. In a large, unselected cohort of patients with cardiogenic shock, 30-day mortality was 26.0%, and non-ischaemic causes accounted for more than 60% of all cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: